According to results presented at the European Academy of Dermatology and Venereology virtual congress, patients with moderate to severe atopic dermatitis had a greater improvement with abrocitinib 100mg or 200mg than with placebo.
A phase 2b and two phase 3 randomised, double-blind, placebo-controlled monotherapy trials evaluated the effect of oral abrocitinib using the Eczema Area and Severity Index in four body regions: head and neck, trunk, lower limbs and upper limbs.
Trunk, lower limb and upper limb subscores saw greater reductions at weeks four, eight and 12 compared with head and neck scores. The upper limbs saw the larger response at week 12.
Dr Jonathan I. Silverberg, one of the study authors, commented, “In this post-hoc analysis, patients with moderate to severe AD treated with abrocitinib 200mg or 100mg had greater improvements – reduction – in the extent of disease and severity of AD signs in all body locations than patients treated with placebo.”
